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The development and clinical validation of nonexercise
pharmacologic stress modalities have proceeded at a dizzy-
ing pace over the past decade . Reports indicate that the
vasodilators dipyridamole and adenosine (and the beta-
agonist dobutamine) yield excellent results in the diagnosis
of coronary artery disease and stress-induced ischemia, and
provide prognostic information after myocardial infarction
and perioperatively. Although Food and Drug Administra-
tion approval of both intravenous dipyridamole and ade-
nosine for cardiac imaging has progressed cautiously, it is
clear that large multicenter safety studies such as those
described in the current report by Cerqueira et al . (1) are
extremely valuable to this approval process . These data, and
previous multicenter reports regarding the side effect profile
of dipyridamole (2,3), represent a significant advance over
previously reported institutional experiences with either
agent. It is now safe to conclude that both agents offer a low
risk alternative to exercise stress in appropriately selected
patients .
Although no direct comparison of these agents has been
published, the power provided by the statistical analysis of
large patient populations permits the detection of subtle but
clinically significant differences between dipyridamole and
adenosine. Specifically, the Adenoscan Multicenter Trial
Registry study (D has identified patients XM years of age as
having a significantly increased risk of atrioventricular (AV)
block, which frequently (28%) necessitated a reduction or
premature termination of the adenosine infusion . Whereas
previous studies have demonstrated the safety (4) and prog-
nostic value (5) of dipyridamole thallium-201 myocardial
imaging in elderly persons, it appears that this side effect
may limit the application of adenosine stress imaging in this
age group. Although adenosine stress imaging can be prog-
nostically (6) and diagnostically (7-9) useful, elderly patients
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may require careful screening for preexisting sick sinus
syndrome and conduction defects and extra vigilance during
adenosine stress testing .
Cerqueira et al. (1) have conclusively demonstrated that
severe reactions to adenosine such as myocardial infarction
(0. 1%), serious bronchospasm (0 .1%) and cardiac death
(0%) are rare, although moderate to severe adverse reactions
did occur in 15% of patients being evaluated by these
experienced investigators . As shown in Table 1, these test-
related morbidity and mortality rates are comparable to
those observed with dipyridamole infusion. Rates of serious
side effects of dipyridamole (2% vs . 2 .5%) and aminophylline
reversal (15% vs . 15%) do not differ between patients >70
versus <70 years old (4) . It is also important to note that
both dipyridamole and adenosine have the potential to
provoke and sustain serious bronchospasm in patients with
extrinsic or intrinsic asthmatic conditions . After the exclu-
sion of vasodilator side effects, dyspnea and nonspecific
chest discomfort, which each occurred in more than one
third of adenosine-tested patients, other less common ade-
nosine-induced adverse reactions were relatively rare and
unpredictable in nature .
It is of some concern that cessation of "short-acting"
adenosine infusion did not universally abort adverse reac-
tions in all patients (1). Seventy-one Adenoscan Registry
patients required additional aminophylline, suggesting that
some adverse reactions may outlast the ultrashort serum
half-life of this agent . Events that are serious enough to
warrant aminophylline reversal can occur even in the hands
of the most experienced stress imaging investigators . Pre-
liminary intracoronary Dcppler flow velocity data from our
medical center suggests that the rate of dipyridamole
(0.56 mg/kg body weight) reversal by 125 mg of aminophyl-
line is slightly slower but comparable to that of cessation of
adenosine infusion (10) .
The relatively high rate (23%) of "delayed or recurrent"
adenosine-related adverse events reported in this study is
somewhat disturbing . Physicians performing dipyridamole
studies have worried about the potential for late vasodilator
side effects after the use of this longer-acting agent, and to
prevent this possibility, they have frequently administered
aminophylline or given caffeine-containing beverages to pa-
tients who are leaving the stress laboratory after dipyrida-
mole testing . The Adenoscan Registry substudy of >10,000
patients at five medical centers suggests that a similar
cautious approach might also be warranted after adenosine
stress testing.
Having raised these concerns, we must reemphasize that
adenosine and dipyridamole are both highly effective coro-
nary and systemic vasodilators that exhibit more similarities
than differences . Side effect profiles for both agents are
largely extensions of these vasodilator actions . Their phar-
macologic interactions are complex and immutable (Fig. 1) .
Although much has been written about the significant bio-
kinetic and AV node receptor differences between these
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Table 1 . Reported Side Effects of Intravenous Adenosine and
Dipyridamole Imaging Multicenter Studies
Figure 1 . Pharmacologic interactions of dipyrida-
mole and adenosine at the level of the vascular
smooth muscle cell membrane (upper portion) and
intracellular messenger (lower portion) . AMP = ad-
enosine monophosphate ; ATP = adenosine triphcs-
phate; cAMP = cyclic adenosine monophosphate
.
*Ventricular arrhythmias
. 1'One subsequent death reported . All data are
reported as percent of patients .
agents (11,12), it is interesting that age, gender and body
habitus remain nonmodifable patient variables that deter-
mine the frequency of adverse events for both adenosine and
dipyridamole studies (1,13,14) .
Multicenter safety data, now available for both adenosine
(1) and dipyridamote (2), have significantly enhanced our
understanding of the relative value of these agents among the
growing list of pharmacologic stress modalities
. In the vast
I Dlpyridomole
majority of clinical subsets with known or suspected coro-
nary artery disease, adenosine and dipyridamole are valu-
able pharmacologic vasodilator stress alternatives . A grow-
ing nu ber of stress laboratories, including our own, keep
both these agents "on the shelf ." However, to suggest that
they are interchangeable would be incorrect, in view of their
different effects on the AV node, particularly in elderly
patients
. Therefore, clinicag judgment is still required in the
process of patient selection for these studies . A more casual
approach could result in unwanted and potentially serious
side effects and frequent premature discontinuation of diag-
nostic studies .
Finally, one would be remiss in not including dobutamine
in any' discussion of pharmacologic stress testing . The use of
this agent with echocardiographic and myocardial perfusion
imaging continues to grow at a rapid pace . Although no large
multicenter study has yet examined the safety and side effect
profile in a fashion similar to studies of dipyridamole and
adenosine, recent reports indicate a safety profile similar to
the profile of these coronary vasodilators . Mertes et al . (15)
reported noncardiac side effects in 26% of 1,118 patients
undergoing dobutamine echocardiographic stress testing,
with chest pain, arrhythmia and AV block occurring in
12.7%, 3.5% and 0.6%, respectively, of patients studied .
In pharmacologic stress imaging (as in parenting), the
issue of whether one agent (or child) is preferred or better
than its sibling seems moot . As the guardians of pharmaco-
`ogic caWdiiac stress imaging, noninvasive cardiologists must
be prepared to acknowledge and accept la di&rence be-
tween these related agents .
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Anti- Platelet
Effects
Adenosine
(present study)
Dipyridatnole
(ref 2)
Noncardiac
Flushing 36.5 3 .4
Dyspnea 35 .2 2 .6
Chest pain 34.6 19,7
Gastrointestinal distress 14.6 5 .6
Headache 14.2 12 .2
Dizziness 8.5 11 .1;
Cardiorespiratory
AV block 7.6 0
ST-T wave changes 5.7 7 .5
Arrhythmia 3 .3 5 .2
Hypotension 1 .8 4 .6
Bronchospasin 0 .1 0 .15
Myocardial infarctior 0 .0001 O .OS
Death ofi 0 .05
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